CSIMarket Company Name, Ticker, Customers, else..


Bio techne Corp  (NASDAQ: TECH)
Other Ticker:  
 

Bio techne Corp

TECH's Fundamental analysis



Bio Techne's sales fell by -4.13 % in I. Quarter 2024 from the same quarter a year ago. Ranking at No. 2556

Biotechnology & Pharmaceuticals industry recorded growth of revenues by 13.29 %

Bio Techne's net profit decreased by -55.49 % in I. Quarter 2024 year on year, to $34 millions.

• More on TECH's Growth


Bio Techne
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Company is currently trading with Price to Cash flow multiple of 1766.74 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
93.99
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 10.66.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.15.


• More on TECH's Valuation
 
 Total Debt (Millions $) 300
 Dividend TTM ($) 0.39 $
 Dividend Yield TTM (%) 0.42 %
 Revenue/Employee (TTM) $ 501,991
 Net Income/Employee (TTM) $ 57,168
 Receivable Turnover (TTM) 5.27
 Tangible Book Value (Per Share $) 4.16

Bio Techne
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Company is currently trading with Price to Cash flow multiple of 1766.74 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
93.99
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 10.66.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.15.

Bio Techne Price to Book Ratio is at 5.76 higher than Industry Avg. of -0, and higher than S&P 500 Avg. of 0.01

• More on TECH's Valuation

•  Market Capitalization (Millions $) 12,312
•  Shares Outstanding (Millions) 161
•  Employees 2,300
•  Revenues (TTM) (Millions $) 1,155
•  Net Income (TTM) (Millions $) 131
•  Cash Flow (TTM) (Millions $) 7
•  Capital Exp. (TTM) (Millions $) -72
•  Total Debt (Millions $) 300
•  Dividend TTM ($) 0.39 $
•  Dividend Yield TTM (%) 0.42 %
•  Revenue/Employee (TTM) $ 501,991
•  Net Income/Employee(TTM) $ 57,168
•  Receivable Turnover Ratio (TTM) 5.27
•  Tangible Book Value (Per Share $) 4.16

•  Market Capitalization (Millions $) 12,312
•  Shares Outstanding (Millions) 161
•  Employees 2,300
•  Revenues (TTM) (Millions $) 1,155
•  Net Income (TTM) (Millions $) 131
•  Cash Flow (TTM) (Millions $) 7
•  Capital Exp. (TTM) (Millions $) -72


    TECH's Profitability Comparisons
Bio Techne achieved increase in profitability, due to cost control. Operating Margin grew in I. Quarter 2024 to 13.84 % from 10.29 % in IV. Quarter.

Bio Techne net profit margin of 11.63 % is currently ranking no. 14 in Biotechnology & Pharmaceuticals industry, ranking no. 99 in Healthcare sector and number 1172 in S&P 500.


Profitability by Segment
Protein Sciences 39.38 %
Diagnostics and Spatial Biology 5.14 %
Total 11.63 %



  Ratio
•   Capital Ratio (MRQ) 4.56
•  Total Debt to Equity (MRQ) 0.14
•  Tangible Leverage Ratio (MRQ) 0.66
•  Asset Turnover Ratio (TTM) 0.44
•  Inventory Turnover Ratio (TTM) 2.21



Bio Techne achieved increase in profitability, due to cost control. Operating Margin grew in I. Quarter 2024 to 13.84 % from 10.29 % in IV. Quarter.

Bio Techne net profit margin of 11.63 % is currently ranking no. 14 in Biotechnology & Pharmaceuticals industry, ranking no. 99 in Healthcare sector and number 1172 in S&P 500.

• More on TECH's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com